News Release

DOACs reduce dementia risk in Asian AFib patients compared to traditional blood thinners

Benefit may reduce with increased age, according to meta-analysis

Peer-Reviewed Publication

American College of Cardiology

The use of direct oral anticoagulants (DOACs) was associated with a reduction in dementia risk compared to traditional blood thinners—like warfarin—in atrial fibrillation patients, particularly in Asian patients. According to a study published today in JACC: Asia, this benefit may reverse with increased age and necessitates further follow-up study.

“Asian patients are more likely to be sensitive to vitamin K antagonism, which puts them at high risk for bleeding events, contributing to dementia development or a reduction in warfarin dose to subtherapeutic levels,” said Vern Hsen Tan, MBBS, senior consultant in the department of cardiology at Changi General Hospital in Singapore and the study’s senior author. “Asians are also often a lower body weight compared to non-Asians, perhaps allowing the DOACs to exert supratherapeutic effects at a standard dose.”

Atrial fibrillation (AFib) is an irregular heart rhythm that can cause blood clots and increases the risk of stroke, heart failure and other related complications. People with AFib are usually treated with medication to reduce the risk of stroke, including traditional blood thinners, such as warfarin, which are anticoagulants that disrupt the blood’s ability to clot but can caused increased risk of bleeding. Direct oral anticoagulants are another option that also interfere with the blood’s ability to clot but are less likely to cause bleeding compared to traditional blood thinners.

Warfarin is more often prescribed for some patients despite the increased bleeding risk because of affordability—DOACs can be expensive and not or only partially reimbursed in certain regions or countries; some patients may have stable therapeutic range (time to therapeutic ratio, TTR >70%) with warfarin and may be reluctant to switch to DOAC; and for certain concomitant medical conditions most physicians prefer warfarin to DOAC.

Stroke is a known risk factor for dementia, while AFib and Alzheimer's dementia appear to be connected regardless of stroke occurrence. It’s unknown whether AFib is directly related to cognitive decline.

Researchers conducted a literature review of studies comparing the incidence of dementia between AFib patients treated with warfarin compared to DOACs. Overall, 10 studies including more than 342,000 patients, were analyzed.

DOAC use was associated with a significantly lower risk of dementia in nine studies when compared to warfarin use. After stratifying by region, a benefit for DOAC was seen in Asian patients but not European patients. Only one study included the American region. A similar benefit for DOACs was seen in patients 65-75 years old, though it was not statistically significant for patients over 75 years old.

In addition to stroke increasing risk of dementia and cognitive decline, there is evidence of stroke-independent risk of dementia in AFib patients. Other proposed factors include dietary intake—patients taking warfarin must limit consumption of vitamin K as it can interfere with how the medication works, whereas patients taking DOACs do not need to limit their vitamin K intake. Low vitamin K levels are associated with both cognitive decline and Alzheimer's disease. Additionally, the green leafy vegetables with high amounts of vitamin K are also often high in B12 and folate, which are associated with lower rates of cognitive decline and dementia. According to the researchers, the benefits of DOACs over warfarin may not be solely related to the impact of DOACs alone.

“Overall, the use of DOACs in AFib significantly reduces dementia risk compared to warfarin,” Tan said. “We would highly recommend DOACs for Asian patients, in particular, as they saw the most benefit of dementia reduction. Nevertheless, the data suggestion of a reversal of this benefit with increasing age warrants further study.”

Study limits include the nonrandomized nature of most studies included in the analysis, as well as the use of disease codes, which only captures patients admitted to the hospital during the study periods.

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its more than 56,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit

The ACC’s family of JACC Journals rank among the top cardiovascular journals in the world for scientific impact. The flagship journal, the Journal of the American College of Cardiology (JACC) — and family of specialty journals consisting of JACC: Advances, JACC: Asia, JACC: Basic to Translational Science, JACC: CardioOncology, JACC: Cardiovascular Imaging, JACC: Cardiovascular Interventions, JACC: Case Reports, JACC: Clinical Electrophysiology and JACC: Heart Failure — pride themselves on publishing the top peer-reviewed research on all aspects of cardiovascular disease. Learn more at


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.